Alan Kingsman is the Chief Executive of Oxford BioMedica pie. He obtained h
is degrees from University of Birmingham, UK, and went on to become a Lectu
rer and Professor at the University of Oxford, UK. In 1993 he became Go-Dir
ector of the Retrovirus Molecular Biology Group within the Biochemistry Dep
artment of Oxford University and was Associate Director of Research at Brit
ish Biotech between 1987 and 1990. In 1995 Professor Kingsman co-founded Ox
ford BioMedica to develop and commercialise gene technologies arising out o
f research undertaken by the Group at the University. The company uses adva
nced gene delivery technologies for the treatment of disease in the areas o
f oncology, viral infection, neurobiology and genetic deficiency. In Decemb
er 1996 Oxford BioMedica was floated on the UK Alternative Investment Marke
t of the London Stock Exchange. Professor Kingsman has published more than
130 papers and reviews and is an internationally recognised authority on ge
ne expression and retrovirus research.